The Optimal Blood Pressure Target for Patients with Coronary Artery Disease

Impact of blood pressure and medication adherence on clinical outcomes in patients with hypertension

Background

Hypertension is a key risk factor for cardiovascular disease. Thus, effective blood pressure (BP) management and adherence to antihypertensive medications are crucial for reducing these risks in patients with hypertension. We evaluated the effect of BP and medication adherence on the clinical outcomes of patients with hypertension.

Methods

This is retrospective cohort study utilized data from the Korean National Health Insurance Database. We analyzed data from 238,950 patients with hypertension aged ≥20 who underwent at least two health checkups between 2009 and 2012. Patients were categorized according to their systolic BP (SBP) and medication adherence. The primary outcome was a composite of all-cause death, myocardial infarction, ischemic stroke, hemorrhagic stroke, and hospitalization for heart failure. Cox proportional hazard models were used to estimate hazard ratios (HR) for composite outcomes.

Results

Higher SBP groups were associated with increased risk of composite outcomes compared to the 120-129 mmHg group (<120 mmHg, HR 1.065; 130-139 mmHg, HR 1.056; 140-149 mmHg, HR 1.068; and ≥150 mmHg, HR 1.238). In addition, across all SBP categories, poor adherence significantly elevated the risk of composite outcomes, even after adjusting for confounding factors. Among all categories, patients with high SBP (≥150 mmHg) and poor adherence had the highest risk.

Conclusion

Higher SBP and poor medication adherence were independently associated with worse clinical outcomes in patients with hypertension. Strategies to enhance medication adherence and achieve optimal BP control are essential to reduce cardiovascular risk.

Treatment strategies for isolated systolic hypertension in elderly patients

INTRODUCTION

Hypertension is a major and modifiable risk factor for cardiovascular disease. Its prevalence is rising as the result of population aging. Isolated systolic hypertension mostly occurs in older patients accounting for up to 80% of cases.

AREAS COVERED

The authors systematically review published studies to appraise the scientific and clinical evidence supporting the role of blood pressure control in elderly patients with isolated systolic hypertension, and to assess the influence of different drug treatment regimens on outcomes.

EXPERT OPINION

Antihypertensive treatment of isolated systolic hypertension significantly reduces the risk of morbidity and mortality in elderly patients. Thiazide diuretics and dihydropyridine calcium-channel blockers are the primary compounds used in randomized clinical trials. These drugs can be considered as first-line agents for the management of isolated systolic hypertension. Free or fixed combination therapy with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and calcium-channel blockers or thiazide-like diuretics should also be considered, particularly when compelling indications such as coronary artery disease, chronic kidney disease, diabetes, and congestive heart failure coexist. There is also hot scientific debate on the optimal blood pressure target to be achieved in elderly patients with isolated systolic hypertension, but current recommendations are scarcely supported by evidence.

Effects of MPO-463G/A and -129G/A polymorphisms on coronary artery disease risk and patient survival in a Turkish population

Myeloperoxidase (MPO) is an oxidative hemoprotein compound expressed in polymorphonuclear leukocytes that contributes to inflammatory responses. Coronary artery disease (CAD), as the most prevalent form of heart disease, is considered to originate from an interaction between genetic and environmental factors. In the present study, the potential associations between MPO-463G/A and -129G/A polymorphisms with CAD were investigated in a Turkish population using a polymerase chain reaction-based restriction fragment length polymorphism (RFLP) assay technique. To the best of our knowledge, the study was the first to examine the association of MPO-463G/A and -129G/A with patient survival rate in a Turkish population. The study population consisted of 201 patients with CAD and 201 healthy controls. The results indicated that there was a significant association of the GA genotype of MPO-463G/A with the case population (P=0.048). Meanwhile, in the patients with CAD, the frequency distributions of the MPO-129A allele (P=0.006) and GA genotype (P=0.001) were significantly increased compared with the G allele and GG genotype, respectively, in CAD patients. Additionally, compared with the GG genotype, the frequency distribution of MPO-129A was significantly increased in the patient group regarding smoking status (P=0.001) and the presence of hypercholesterolemia (P=0.028). However, survival analysis did not detect an effect of either polymorphism on the survival rate of the CAD patients (P>0.05). Therefore, the MPO-129GA genotype may be a significant risk factor for the development of CAD.

Considerations in Understanding the Coronary Blood Flow- Left Ventricular Mass Relationship in Patients with Hypertension

Abstract: Background: Coronary blood flow (CBF) is essential for optimal cardiac performance and to maintain myocardial viability. There is considerable ambiguity concerning CBF in hypertension.

Objective: To investigate the relationship between CBF and left ventricular (LV) mass in persons with hypertension.

Methods: OvidSP Medline was systematically searched. Eligible articles assessed CBF, and LV mass in adults with and without hypertension (HTN).

Results: Eleven studies met the entry criteria. All 8 studies reported an increase in CBF (ml/min) for persons with hypertension (N=212) compared to individuals without hypertension (N=150). Meta-analysis showed a significant and 2.88 fold higher CBP in hypertension. Six studies adjusted CBF for LV mass; of which 4 studies reported a reduction in CBF. Meta-analysis showed a significant decrease in CBF/g LV mass in hypertension. The two studies that did not show a decrease in CBF, used the argon chromatographic method to measure coronary sinus blood flow suggesting this methodology may have influenced the results. Using the mean CBF in normotensive group to construct the expected CBF according to LV mass, reported CBF in HTN was progressively less than expected In two studies, (N=142), there was a significant inverse correlation between LV mass and CBF/ g LV mass. Multivariate analysis (three studies) consistently found a highly significant independent relationship between LV mass and CBF after considering age, sex, heart rate and several other factors.

Conclusion: Hypertension is associated with a reduction in CBF adjusted for LV mass with a highly significant inverse association between CBF and LV mass. Clinicians should be aware that patients with hypertension are at greater risk for myocardial ischemia should develop other factors that limit CBF or myocardial oxygen delivery.

Metabolic syndrome and its individual components with mortality among patients with coronary heart disease

BACKGROUND

The metabolic syndrome (MetS) and its metabolic risk factors appear to promote the development of atherosclerotic cardiovascular disease. The aim of this study was to examine the association of MetS and its individual components with all-cause and cardiovascular mortality among patients with coronary heart disease (CHD).

METHODS

We performed a prospective, hospital-based cohort among 3599 CHD patients in China. Cox proportional hazards regression models were used to estimate the association of MetS and its components at baseline with risk of mortality.

RESULTS

During a mean follow-up period of 4.9years, 308 deaths were identified, 200 of which were due to cardiovascular disease. Compared with patients without MetS, patients with MetS according to the AHA/NHLBI statement had a 1.26-fold higher risk (95% CI, 1.01-1.59) of all-cause mortality and a 1.41-fold higher risk (1.06-1.87) of cardiovascular mortality. Patients with increasing numbers of components of MetS had a gradually increased risk for all-cause and cardiovascular mortality (P<0.05). When each component of MetS was considered as a dichotomized variable separately, only low high-density lipoprotein cholesterol (HDL-C) and elevated fasting blood glucose (FBG) were associated with all-cause and cardiovascular mortality. After using restricted cubic splines, we found a U-shaped association of HDL-C, body mass index and blood pressure, a positive association of FBG, and no association of triglycerides with the risks of all-cause and cardiovascular mortality.

CONCLUSIONS

MetS is a risk factor for all-cause and cardiovascular mortality among CHD patients. It is very important to control metabolic components in a reasonable control range.

What should be the optimal levels of blood pressure: Does the J-curve phenomenon really exist?

INTRODUCTION

The blood pressure (BP) J-curve debate has lasted for over 30 years and we still cannot definitively answer all the questions. However, recent studies suggest that BP should be reduced carefully in patients with hypertension and coronary artery disease. BP should not fall below 110 - 115/70 - 75 mmHg, because this may be associated with more cardiovascular events.

AREAS COVERED

A retrospective analysis of the INVEST Trial and the results of the BP arm of the ACCORD Trial shows that care is needed in patients with hypertension and diabetes. Although the ACCORD BP Trial suggests important benefits connected with the significant reduction of stroke in patients being treated intensively, it also shows the lack of advantage of such therapy on each main and other additional endpoints. The ACCORD Trial also confirmed the increased risk of adverse events that might appear when intensive treatment was used in this group of patients.

EXPERT OPINION

Most available studies were observational and randomized trials (BBB, HOT, ACCORD BP), do not have or have lost their statistical power and were inconclusive. Further studies are therefore needed to provide definitive conclusions on the subject. In the meantime, it seems that in high-risk patients with hypertension, it is necessary to carefully select those who might suffer adverse events and those who may benefit from intensive BP lowering.